PCK1 and hepatocellular carcinoma: By inhibiting the rate-limiting enzyme phosphoenolpyruvate carboxykinase (PEPCK1) sumoylation and diverting glucose metabolism toward gluconeogenesis, Nur77 inhibited the development of hepatocellular carcinoma by causing ATP depletion and stopping cell proliferation [29].